Mohammad Al-Akchar, MD
Cardiovascular Disease · Urbana, ILNPI 1730561903
Payments from drug & device makers
Across 21 payments — averaging $54.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$428
- Johnson & Johnson$297
- Heartflow, Inc.$189
- Cleerly, Inc.$71
- Baxter Healthcare$30
- Vifor Pharma, Inc.$20
- plus $101 from 6 others
What the payments were for
- Food & beverage$98487%
- Education$15113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 4 | $428 |
| Johnson & Johnson | 3 | $297 |
| Heartflow, Inc. | 3 | $189 |
| Cleerly, Inc. | 2 | $71 |
| Baxter Healthcare | 2 | $30 |
| Vifor Pharma, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Kestra Medical Technology Services, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$233
- ENSITE PRECISION$151
- CARDIOMEMS$143
- ASSURITY$115
How this compares
$1,136 in reported general payments places this provider in the 40th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $31,177 |
| Rosuvastatin Calcium | 28 | $583 |
| ClopidogrelClopidogrel Bisulfate | 14 | $352 |
| Metoprolol Succinate | 30 | $282 |
| Furosemide | 28 | $247 |
| Losartan Potassium | 19 | $213 |
| Amlodipine Besylate | 16 | $186 |
| Atorvastatin Calcium | 20 | $179 |
| Metoprolol Tartrate | 31 | $157 |
| Lisinopril | 16 | $154 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Urbana
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Lokesh ChandraHazel Crest$2.7M
- Steven LupovitchArlington Heights$2.6M
- Nitasha SarswatChicago$2M
- Alan BrownNaperville$1.5M
- Alexander AdlerPeoria$1.5M
- Clifford KavinskyMaywood$1.4M
- Sanjiv ShahChicago$1.2M
- Sandeep NathanChicago$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.